T. Rowe Price Associates
FMTX

T. Rowe Price Associates’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

T. Rowe Price Associates’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,795
Closed -$156K – 3027
2022
Q1 		$156K Buy
16,795
+800
+5% +$8.52K ﹤0.01% 2765
2021
Q4 		$227K Buy
+15,995
New +$277K ﹤0.01% 2710

Other funds holding FMTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
EPL
EDBI Pte Ltd Singapore $94.4M AUM 32.71% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates's FMTX Position: Q2 2022 in Review

T. Rowe Price Associates sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q2 2022, closing a stake of 16,795 shares — an estimated $156K sold.

T. Rowe Price Associates first reported a position in FMTX in Q4 2021 and held it in 2 quarters. The position peaked at $227K in Q4 2021. 105 funds tracked by Wall St. Rank hold FMTX as of Q2 2022.

  • T. Rowe Price Associates reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 16,795 Forma Therapeutics Holdings, Inc. Common Stock shares in Q2 2022, an estimated $156K.
  • T. Rowe Price Associates first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • T. Rowe Price Associates's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $227K in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q2 2022.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.